8-K: EyePoint Pharmaceuticals Announces Positive Phase 2 Results for DURAVYU in Diabetic Macular Edema

EyePoint Pharmaceuticals reports positive six-month results from its Phase 2 VERONA trial of DURAVYU for diabetic macular edema, meeting primary and secondary endpoints.

Summary

• EyePoint Pharmaceuticals announced positive six-month results from the Phase 2 VERONA clinical trial evaluating DURAVYU for diabetic macular edema (DME).
• The trial met its primary endpoint, showing extended time to first supplemental injection compared to aflibercept control for both DURAVYU doses (1.34mg and 2.7mg).
• The DURAVYU 2.7mg dose demonstrated a +7.1 letter improvement in BCVA and a 76-micron reduction in CST at week 24.
• 73% of eyes in the DURAVYU 2.7mg arm were supplement-free versus 50% in the aflibercept control arm up to week 24.
• The company anticipates initiating a Phase 3 non-inferiority pivotal program by the end of 2025.
• The company's ongoing Phase 3 trials in wet AMD are on track to read out in 2026.
• The company had approximately $370M in cash and equivalents as of December 31, 2024.
• The company opened a new commercial manufacturing facility in October 2024.

Sentiment

Score: 9

Explanation: The document presents highly positive clinical trial results, indicating a potential breakthrough in DME treatment. The management's optimistic statements and the company's strong financial position further contribute to the positive sentiment.

Positives

• DURAVYU demonstrated statistically significant improvements in visual acuity and anatomical outcomes in DME patients.
• The treatment burden was reduced by two-thirds with the 2.7mg dose of DURAVYU.
• DURAVYU has a favorable safety profile with no DURAVYU-related ocular or systemic serious adverse events reported.
• The company has a strong cash position of approximately $370 million, providing a cash runway into 2027.
• The company opened a new commercial manufacturing facility in October 2024.

Risks

• The forward-looking statements are subject to risks and uncertainties, including the timing, progress, and results of clinical development activities.
• Uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials could impact the company's plans.
• The company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated.
• Unexpected safety or efficacy data observed during clinical trials could impact the company's plans.
• Uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorneys Office for the District of Massachusetts could impact the company's plans.
• Uncertainties regarding the FDA warning letter pertaining to the company's Watertown, MA manufacturing facility could impact the company's plans.

Future Outlook

EyePoint anticipates initiating a Phase 3 pivotal program for DURAVYU in DME by the end of 2025 and expects topline data from its Phase 3 pivotal trials in wet AMD in 2026. The company is also continuing the clinical development of other product candidates, including EYP-2301.

Management Comments

• Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint, stated that the VERONA results demonstrate that 2.7mg DURAVYU immediately and meaningfully improves both visual acuity and anatomy in DME patients with a superior dosing interval and excellent safety.
• Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer, stated that the data from the Phase 2 VERONA trial demonstrated that within four weeks, eyes treated with DURAVYU had a significant benefit for patients with DME, both visually and anatomically.
• Carl Regillo, M.D., FACS, Chief of Retina Service at Wills Eye Hospital and Co-Chair of EyePoint's SAB, stated that DURAVYU features zero order kinetics release, so the VEGF receptors remain blocked for at least six months enabling the ability to extend dosing intervals while maintaining the patients vision.

Industry Context

The results are significant as DME is a leading cause of vision loss in working-age adults, and there is a need for more durable treatments. DURAVYU's potential to reduce treatment burden and improve visual outcomes could make it a competitive option in the DME market.

Comparison to Industry Standards

• The current standard of care for DME includes intravitreal injections of anti-VEGF biologics like aflibercept (Eylea), corticosteroids, or laser photocoagulation.
• DURAVYU aims to provide a more durable treatment option, potentially reducing the frequency of injections compared to existing anti-VEGF therapies.
• The 73% supplement-free rate at 24 weeks with DURAVYU 2.7mg compares favorably to the 50% rate in the aflibercept control arm, suggesting a potential for reduced treatment burden.
• The company is pursuing a non-inferiority trial design in wet AMD, suggesting they aim to demonstrate similar efficacy to aflibercept while offering advantages such as reduced injection frequency.

Management Changes

Legal Proceedings

• The company is subject to uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorneys Office for the District of Massachusetts.

Stakeholder Impact

• Shareholders: Positive clinical trial results could lead to increased stock value.
• Patients: DURAVYU offers a potential new treatment option with reduced treatment burden.
• Physicians: DURAVYU could provide a more effective and convenient treatment option for DME patients.

Next Steps

• Continue development of Phase 3 clinical protocol for DME.
• Discuss Phase 2 results and proposed Phase 3 clinical protocol with regulatory agencies (FDA, EMA).
• Initiate Phase 3 pivotal program for DME anticipated by the end of 2025.
• Present results at future medical conferences.

Key Dates

Keywords

DURAVYU, diabetic macular edema, DME, wet AMD, vorolanib, retinal diseases, EyePoint Pharmaceuticals, clinical trial, BCVA, CST, aflibercept, Durasert E